Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. (Q51550263)

From Wikidata
Jump to navigation Jump to search
scientific article published on 23 January 2005
edit
Language Label Description Also known as
English
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.
scientific article published on 23 January 2005

    Statements

    Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit